Enhanced pathogenicity of Th17 cells due to natalizumab treatment: Implications for MS disease rebound.
Janoschka C, Lindner M, Koppers N, Starost L, Liebmann M, Eschborn M, Schneider-Hohendorf T, Windener F, Schafflick D, Fleck AK, Koch K, Deffner M, Schwarze AS, Schulte-Mecklenbeck A, Metz I, Meuth SG, Gross CC, Meyer Zu Hörste G, Schwab N, Kuhlmann T, Wiendl H, Stoll M, Klotz L.
Janoschka C, et al. Among authors: schafflick d.
Proc Natl Acad Sci U S A. 2023 Jan 3;120(1):e2209944120. doi: 10.1073/pnas.2209944120. Epub 2022 Dec 27.
Proc Natl Acad Sci U S A. 2023.
PMID: 36574650
Free PMC article.